<scp>DKK1</scp> drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with <scp>anti‐DKK1</scp> therapeutic <scp>DKN</scp> ‐01Edward J. Jarman, Luke Boulter, Marta Horcas‐Lopez et al.|Liver International|2022Cited by 20
A TGFβ-ECM-integrin signaling axis drives structural reconfiguration of the bile duct to promote polycystic liver diseaseScott H. Waddell, Luke Boulter, Ava Khamseh et al.|Science Translational Medicine|2023Cited by 20
<i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target CholangiocarcinomaNicholas T. Younger, Luke Boulter, Mollie L. Wilson et al.|Cancer Research|2022Cited by 17
Van Gogh-like 2 is essential for the architectural patterning of the mammalian biliary treeMichaela Raab, Luke Boulter, Ersi Christodoulou et al.|Journal of Hepatology|2024Cited by 8
Supplementary Data from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target CholangiocarcinomaNicholas T. Younger, Luke Boulter, Mollie L. Wilson et al.|Unknown|2023Cited by 0